Your search history is turned on.
Date: May 8, 2024 12:52:17 EST Jurisdictions: British Columbia, Ontario
Lexaria Begins Dosing of its Second GLP-1 Human Pilot Study Kelowna, British Columbia May 8, 2024 Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the Company or Lexaria), a global innovator in drug delivery platforms announces that human pilot study #2, GLP-1-H24-2, (the Study) is underway and the first dosing visit for all nine study participan...
Date: May 6, 2024 Jurisdictions: British Columbia, Ontario
Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs Kelowna, British Columbia May 6, 2024 Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the Company or Lexaria), a global innovator in drug delivery platforms announces an applied research program to evaluate certain molecular characteristic...
Date: May 2, 2024 Jurisdictions: British Columbia
Create report of exempt distribution (Form 45-106F1) Form 45-106F1 Report of Exempt Distribution ITEM 1 - REPORT TYPE New report Amended report If amended, provide filing date of report that is being amended. (YYYY-MM-DD) ITEM 2 - PARTY CERTIFYING THE REPORT Indicate the party certifying the report (select only one). For guidance regarding whether an ...
Date: April 30, 2024 Jurisdictions: British Columbia, Ontario
Lexaria Bioscience Corp. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 30, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000...
Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance Kelowna, British Columbia April 30, 2024 Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the Company or Lexaria), a global innovator in drug delivery platforms announces it has entered into a warrant exercise agreement with an existing accredited investor to exercise...
Date: April 24, 2024 Jurisdictions: British Columbia, Ontario
Lexaria Bioscience Corp. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 23, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada ...
Date: April 16, 2024 Jurisdictions: British Columbia, Ontario
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study Human Pilot Study #2 (GLP-1-H24-2) Approved Kelowna, British Columbia April 16, 2024 Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the Company or Lexaria), a global innovator in drug delivery platforms, announces approval has been received from an independent third-party...
Date: April 9, 2024 Jurisdictions: British Columbia, Ontario
Section 302 Certification (Form 10-K/A) CFO (W0033807).DOC EXHIBIT 31.2 CERTIFICATION PURSUANT TO 18 U.S.C. ss 1350, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Nelson Cabatuan, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Lexaria Bioscience Corp.; 2. Based on my knowledge, th...
Section 302 Certification (Form 10-K/A) CEO (W0033808).DOC EXHIBIT 31.1 CERTIFICATION PURSUANT TO 18 U.S.C. ss 1350, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Christopher Bunka, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Lexaria Bioscience Corp.; 2. Based on my knowledge, ...
Lexaria Bioscience Corp. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 29, 2024 or TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For ...